High Growth Tech Stocks in France for October 2024

In This Article:

As the French CAC 40 Index experiences modest gains amid broader European optimism for potential interest rate cuts, the high-growth tech sector in France remains a focal point for investors seeking opportunities in an evolving market landscape. Identifying promising stocks often involves looking at companies with innovative technologies and strong growth potential, especially as economic conditions and policy shifts create a dynamic backdrop.

Top 10 High Growth Tech Companies In France

Name

Revenue Growth

Earnings Growth

Growth Rating

Icape Holding

17.24%

33.91%

★★★★★☆

Archos

25.98%

77.41%

★★★★★☆

Valneva

22.83%

17.91%

★★★★★☆

Valbiotis

43.33%

42.78%

★★★★★☆

Munic

42.94%

174.09%

★★★★★☆

Oncodesign Société Anonyme

14.68%

101.18%

★★★★★☆

beaconsmind

25.00%

78.71%

★★★★★★

Adocia

70.20%

63.97%

★★★★★☆

VusionGroup

28.35%

81.72%

★★★★★★

Pherecydes Pharma Société anonyme

63.30%

78.85%

★★★★★☆

Click here to see the full list of 40 stocks from our Euronext Paris High Growth Tech and AI Stocks screener.

Here's a peek at a few of the choices from the screener.

Genfit

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Genfit S.A. is a late-stage biopharmaceutical company focused on discovering and developing drug candidates and diagnostic solutions for metabolic and liver-related diseases, with a market cap of €282.41 million.

Operations: Genfit focuses on the research and development of innovative medicines and diagnostic solutions for metabolic and liver-related diseases, generating €80.47 million in revenue from these activities. The company operates within a niche biopharmaceutical sector, emphasizing the creation of drug candidates and diagnostics.

Genfit S.A. has demonstrated a remarkable turnaround, with its first-half 2024 revenues soaring to €61.2 million from €15.37 million in the previous year, underpinned by a significant shift to profitability at €30.31 million net income compared to a loss of €20.85 million year-over-year. This financial rejuvenation is echoed in its earnings growth forecast, which at 33.8% annually, outpaces the broader French market's expectation of 12%. Despite challenges like a highly volatile share price and low forecasted return on equity at 5.5% in three years, Genfit's strategic focus on R&D could be pivotal; however, specific figures on recent R&D expenditures are not provided here but are crucial for evaluating its long-term innovation potential and competitive edge in the biotech sector.